Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Update

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 92,800 shares, a growth of 16.4% from the February 13th total of 79,700 shares. Approximately 3.1% of the company’s stock are short sold. Based on an average daily volume of 978,200 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Chardan Capital decreased their target price on Sonnet BioTherapeutics from $30.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, December 20th.

Institutional Investors Weigh In On Sonnet BioTherapeutics

An institutional investor recently bought a new position in Sonnet BioTherapeutics stock. Virtu Financial LLC bought a new stake in Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 39,647 shares of the company’s stock, valued at approximately $58,000. Virtu Financial LLC owned approximately 1.30% of Sonnet BioTherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 9.45% of the stock is owned by institutional investors and hedge funds.

Sonnet BioTherapeutics Stock Performance

Shares of NASDAQ:SONN opened at $1.38 on Wednesday. Sonnet BioTherapeutics has a twelve month low of $1.30 and a twelve month high of $18.62. The business has a 50 day moving average price of $1.55 and a 200 day moving average price of $2.38.

Sonnet BioTherapeutics (NASDAQ:SONN) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($1.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($11.12) by $9.56. The company had revenue of $1,000 billion for the quarter.

Sonnet BioTherapeutics Company Profile

Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.